The main focus of the research group is in translational research in gynaecological cancers. In particular biomarker discovery and development (specifically immunological markers) in ovarian and endometrial cancers. The biomarkers are now in the process of being tested for diagnosis and surgical prognosis. The concept of predicting surgical outcome in ovarian cancer is a step in developing personalised medicine and providing patients with best care possible.
Recent advances in oncolgy have improved survival in patients with cancer but research into surgery may have additional benefits for the patient. Clinical research into optimal treatment of cervival preinvasive lesions has been a focus. We have shown that clear margins of resection has a significant effect on reducing risk of recurrence from preinvasive disease.
et al., 2018, Genes predisposed to DNA hypermethylation during acquired resistance to chemotherapy are identified in ovarian tumors by bivalent chromatin domains at initial diagnosis., Cancer Res
Flower KJ, Ghaem-Maghami S, Brown R, 2018, Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?, Current Cancer Drug Targets, Vol:18, ISSN:1568-0096, Pages:5-15
et al., 2017, Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer, Clinical Cancer Research, Vol:23, ISSN:1078-0432, Pages:3453-3460
et al., 2017, Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study, British Journal of Cancer, Vol:116, ISSN:0007-0920, Pages:1287-1293
et al., 2017, Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20, Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), AMER SOC CLINICAL ONCOLOGY, ISSN:0732-183X